Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to drug research and development, today announced their newest Science Advisory Board member, Dhaval K. Shah, PhD.
Dr. Shah is an Assistant Professor of Pharmaceutical Sciences at the State University of New York at Buffalo. His research focuses on understanding the determinants for the absorption, distribution, metabolism, and elimination (ADME) of protein therapeutics, and is funded by the National Institutes of Health, The Center for Protein Therapeutics at the University at Buffalo, and several pharmaceutical companies. His lab uses the principles of pharmacokinetics and pharmacodynamics (PK/PD) modeling and simulation to support the discovery, clinical translation, and late phase development of novel biologics like engineering antibodies, antibody-drug conjugates, multi-specific proteins, immuno-oncology agents, and engineered T cells.
During his time at the State University of New York at Buffalo, Shah pioneered the development of translational systems pharmacokinetic models for protein therapeutics, and also developed experimental techniques (e.g. microdialysis and imaging) to support the development of these models for challenging tissues like solid tumors, eye, and brain.
Dr. Shah brings his PK/PD modeling and simulation expertise to Applied BioMath, known for its Model-Aided Drug Invention (MADI) approach to drug research and development. MADI leverages mechanistic PK/PD and systems pharmacology, which quantitatively integrates knowledge about therapeutics with an understanding of mechanism of action in the context of human disease mechanisms. Shah is the most recent of several key opinion leader to join Applied BioMath's Science Advisory Board, joining Joseph Loscalzo MD PhD, Werner Meir, Bruce Tidor PhD, Mike Yaffe MD PhD, and Douglas A. Lauffenburger PhD on the board.
"We are excited to welcome Dr. Shah to our Science Advisory Board," said Joshua Apgar PhD, Co-Founder and CSO at Applied BioMath. "His leadership in extending the state of the art for PBPK modeling and simulation for biotheraputics makes him an invaluable resource as we [Applied BioMath] continue to expand our services in various therapeutic areas."
"I have known Dr. Shah for almost 10 years, and have always been very impressed by his science, thoughtfulness, and kindness. I am very excited to see him join our SAB," said John Burke PhD, Co-founder and CEO at Applied BioMath.
Prior to his current role, Shah served as Principal Scientist in the Translational Research - Modeling and Simulation group at Pfizer, Inc. Shah earned his Ph.D. in Pharmaceutical Sciences from the State University of New York at Buffalo in 2010.
About Applied BioMath
Founded in 2013, Applied BioMath uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development. Their Model-Aided Drug Invention (MADI) approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through clinical trials. The Applied BioMath team leverages their decades of expertise in biology, mathematical modeling and analysis, high-performance computing, and industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, patients, and the best path forward into and in the clinic. For more information about Applied BioMath and its services, visit www.appliedbiomath.com.
Applied BioMath and the Applied BioMath logo are registered trademarks of Applied BioMath, LLC.
Press contact:
Kristen Zannella
kristen.zannella@appliedbiomath.com